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Abstract Recent data demonstrate that patients affected
with hypokalemic salt-losing tubulopathies are prone to
acute cardiac arrhythmias and rhabdomyolysis. The
tendency to these potentially fatal complications is
especially high if chronic hypokalemia is severe, in
patients with diarrhea, vomiting or a prolonged QT
interval on standard electrocardiography, in patients on
drug management with compounds prolonging the elec-
trocardiographic QT interval (including antiarrhythmic
agents, some antihistamines, macrolides, antifungals,
psychotropics, ß2-adrenergic agonists or cisapride), fol-
lowing acute alcohol abuse and during exercise. Cardiac
arrhythmias and rhabdomyolysis occur with sufficient
frequency in hypokalemic salt-losing tubulopathies to merit
wider awareness of their presence and the preparation of
specific prevention and management recommendations.
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Hypokalemic salt-losing tubulopathies, such as Bartter
and Gitelman syndromes, are a group of closely related
tubular disorders, first described in 1962, which are
transmitted as autosomal recessive traits. All Bartter–
Gitelman patients share several characteristics, including
hypokalemia (with or without concurrent hypomagnese-
mia), metabolic alkalosis, normal or low blood pressure,
and activated renin–angiotensin–aldosterone and
prostaglandin–kinin systems [1–3].
Thirteen years ago, a boy with unclassified Bartter–
Gitelman syndrome in our care died suddenly [4]. Since
potassium depletion, with or without concurrent magne-
sium depletion, imparts an increased risk for developing
cardiac arrhythmias culminating in syncope or even sudden
death (this link is very well documented for patients
managed with thiazide diuretics), we attributed the death
to hypokalemia [5–9].
A prolonged QT interval on standard electrocardiography
[10, 11] imparts an increased risk for developing a
ventricular arrhythmia culminating in syncope or sudden
death (Fig. 1). In agreement with this finding, we have
observed during years of clinical practice that the QT-interval
is often prolonged in patients with Gitelman syndrome,
which is the most frequent variant of these syndromes,
leading us to speculate that these patients are of an increased
risk of developing dangerous cardiac arrhythmias [12].
However, continuous ambulatory electrocardiography and
C. Cortesi : S. A. G. Lava :M. G. Bianchetti
Department of Pediatrics, Mendrisio and Bellinzona Hospitals,
University of Bern,
Bern, Switzerland
A. Bettinelli : F. Tammaro
Department of Pediatrics, San Leopoldo Mandic Hospital,
Merate, Italy
O. Giannini
Nephrology and Internal Medicine Services,
Ospedale Regionale Beata Vergine,
Mendrisio, Switzerland
M. Caiata-Zufferey
Institute of Communication and Health,
Università della Svizzera Italiana,
Lugano, Switzerland
M. G. Bianchetti (*)
San Giovanni Hospital,
6500 Bellinzona, Switzerland
e-mail: mario.bianchetti@pediatrician.ch
Pediatr Nephrol (2010) 25:2005–2008
DOI 10.1007/s00467-010-1580-4
exercise testing failed to detect significant abnormalities of
cardiac rhythm in our Gitelman patients [13]. Nonetheless,
since both hypokalemia and hypomagnesemia were rather
mild in these patients, we presumed [14] that dangerous
cardiac arrhythmias may occur in patients with severe
hypokalemia (and hypomagnesemia), as indicated by the
case of a newborn with profound hypokalemia in the context
of the antenatal form of Bartter syndrome, who developed
severe cardiac arrhythmias and cardiac arrest [15].
Considering the persisting uncertainty related to the
possible occurrence of cardiac arrhythmias culminating in
syncope or sudden death in the context of Bartter–Gitelman
syndromes, we conducted a survey/inquiry among physi-
cians caring for Bartter–Gitelman children, which disclosed
four patients with lethal and three with severe non-lethal
cardiac arrhythmias [16]. Six recent case reports support the
assumption that hypokalemia may cause dangerous cardiac
arrhythmias in Bartter–Gitelman patients [17–21].
In addition to its potential to cause cardiac arrhyth-
mias, severe hypokalemia may effect dissolution of the
peripheral striated muscle fibers with leakage of the
intracellular constituents, a distinctive condition known
as rhabdomyolysis [22, 23]. The immediate consequences
of rhabdomyolysis include hyperkalemia (and hyperphos-
phatemia) resulting from the release of potassium and
phosphorous from damaged muscle, which in turn may
cause cardiac arrhythmias, and acute kidney injury. In fact,
two recent reports indicate that Bartter–Gitelman patients
occasionally do develop rhabdomyolysis [24, 25].
Based on the afore-mentioned data, we offer some take-
home messages relevant to the prevention of hazardous
cardiac arrhythmias and rhabdomyolysis in patients affected
with hypokalemic salt-losing tubulopathies. The value of
our advice should be confirmed in long-term observational
studies.
1) Severe chronic hypokalemia (≤2.5 mmol/L) is hazard-
ous [5–7]. Consequently, in addition to potassium salts
and cyclooxygenase inhibitors [1, 2], potassium-
sparing diuretics and blockers of the renin–angioten-
sin–aldosterone system deserve consideration in patients
with refractory hypokalemia or with gastrointestinal side
effects secondary to potassium supplementation or
medication with nonselective anti-inflammatory drugs.
However, very limited clinical experience has been
reported to date with blockers of the renin–angiotensin–
aldosterone system in these patients [26, 27].
2) In Bartter–Gitelman patients, acute diarrhea or
vomiting [16], even if mild, may cause very severe
hypokalemia (≤2.0 mmol/L). In this setting, early
referral and prompt electrolyte and fluid repair are of
paramount importance, since the repair of hypokale-
mia with oral potassium supplementation, potassium-
sparing diuretics, cyclooxygenase inhibitors, and
blockers of the renin–angiotensin–aldosterone system
often meets with limited success. In fact, hypokalemia
is largely secondary to extracellular fluid volume
depletion, a potent stimulus for the renin–angioten-
sin–aldosterone system [28], suggesting that address-
ing directly extracellular fluid volume depletion might
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Fig. 1 Electrocardiographic changes induced by hypokalemia are a
flat or even inverted T wave (a), a depressed ST segment (b), and the
presence of a U wave (c). Other findings, especially in the presence of
coexistent hypomagnesemia, include a prolonged QT interval,
ventricular extrasystoles, ventricular tachycardia, torsades de pointes,
and ventricular fibrillation. The figure depicts the electrocardiographic
signals in a female patient with the presumed diagnosis of Bartter
syndrome admitted with a potassium level of 1.4 mmol/L. The figure
illustrates electrocardiography at presentation and following an initial
correction of hypokalemia
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be a further, hitherto rather neglected treatment option
for hypokalemia [3]. It is therefore tempting to advise
a more liberal fluid and salt intake in order to prevent
—at least in part—the tendency toward severe,
chronic hypokalemia. Conversely, in patients with
acute diarrhea and vomiting, parenteral rehydration
with isotonic saline may be as important as direct
potassium replacement to treat very severe hypokale-
mia. One further critical therapeutic principle con-
cerns the intravenous administration of potassium in
glucose-free solutions, since this sugar may cause a
further decrease in potassium level, precipitating
arrhythmias and rhabdomyolysis [7].
3) A prolonged QT interval on standard electrocardiography
imparts an increased risk for the development of cardiac
arrhythmias, culminating in syncope or sudden death that
reflects both acquired (including potassium levels) and
congenital factors [10, 11]. Considering that a prolonged
QT interval has been associated with Bartter–Gitelaman
syndromes whatever the potassium levels, the QT
interval has to be systematically measured in these
patients. In those patients with a prolonged QT interval,
potassium levels have to be more closely (≥3.0 mmol/L)
controlled.
In Bartter patients with a prolonged QT interval (Table 1),
as in patients with hypertrophic cardiomyopathy, coronary
artery anomalies, Marfan syndrome, aortic stenosis, and
Wolff–Parkinson–White syndrome, exercise or participation
in recreational and, especially, competitive sports is
associated with some risk of sudden cardiac death [10, 11].
In these patients, a history of syncope is a further powerful
predictor of life-threatening cardiac events [10, 11]. As a
consequence, Bartter–Gitelman patients with a prolonged QT
interval should avoid getting involved in competitive sports.
This recommendation is supported by the results of a study
that demonstrated an impaired capacity to adapt left
ventricular function in response to exercise in Bartter–
Gitelman patients [29]. Considering that the recommendation
is often hard on adolescents and adults involved in
competitive sport activities, we usually seek the advice of a
cardiologist.
Finally, in Bartter patients, further promoters of cardiac
arrhythmias or rhabdomyolysis deserve consideration.
1) In patients with either a congenital or acquired long QT
interval, acute alcohol abuse and a number of com-
pounds (including antiarrhythmic agents, some antihist-
amines, macrolides, antifungals, psychotropics, β2-
adrenergic agonists or cisapride) may cause a further
QT prolongation and, therefore, cardiac arrhythmias
[10, 11].
2) Conversely, alcohol abuse and both illicit (most
frequently cocaine or ecstasy) and prescribed drugs
(most frequently statins and antipsychotic drugs) are
potentially myotoxic. The spectrum of severity is broad
and varies from an asymptomatic increase in blood
creatine kinase level to acute rhabdomyolysis. Hence,
we assume (but can not prove) that these factors may
enhance the tendency towards rhabdomyolysis in
Bartter syndrome [22, 23]. Educating Bartter patients,
their family members and their family physicians on
alcohol abuse and illicit or prescribed drugs that may
prolong the QT interval or cause myotoxicity is of
tremendous importance.
In conclusion, improving the outcome of rare diseases
is of the utmost concern. Cardiac arrhythmias and
rhabdomyolysis occur, in our opinion, with sufficient
frequency in Bartter–Gitelman patients to merit a wider
awareness of their presence and the preparation of specific
prevention and management recommendations.
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